Clinical trials: Lung Allograft Transplantation
Lung Transplantation
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
Background: People who have lung transplants often survive 6 or 7 years. But some people develop donor-specific antibodies (DSA) after their transplants; antibodies are proteins that attack foreign invaders in the body.
- Trial name
- NCT06948097
- Testing
- fostamatinib
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Heart Transplantation, Lung Transplantation
Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®
Comparison of tacrolimus blood levels in adults who have received a transplant and are taking either Prograf or Advagraf anti-rejection therapy immediately following surgery.
- Conditions
- Heart Transplantation, Lung Transplantation, Pancreas (Including SPK) Transplantation
- Trial name
- NCT01332201
- Testing
- Advagraf, Prograf
- Where
- 8 sites in Austria, Belgium and 4 more
- Volunteers
- 17 people
- Sponsor
- Astellas Pharma Inc
Chronic Lung Allograft Dysfunction (CLAD)
Breath Volatile Organic Compounds Patterns of Lung Transplant Patients With Chronic Lung Allograft Dysfunction
It's the aim of this study to clarify, whether the non-invasive assessment of breath can serve as a novel clinical tool to assist in the diagnosis of CLAD.
- Trial name
- NCT02836938
- Testing
- Collection of exhaled breath volatile organic compounds
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Prof. Dr. Jens Hohlfeld
Lung Transplant Rejection, Primary Graft Dysfunction
Exhaled Breath Particles in Lung Transplantation
Lung transplantation (LTx) is the only effective treatment for patients with end stage lung disease. Of the major organs transplanted, survival following LTx is the lowest with a mean of 5 years.
- Conditions
- Lung Transplant Rejection, Primary Graft Dysfunction, Chronic Rejection of Lung Transplant
- Trial name
- NCT05375149
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Lund University Hospital
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans
Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
This study is for people who have had a lung transplant and developed a condition called chronic lung allograft dysfunction (CLAD), which is a type of chronic rejection.
- Conditions
- Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
- Trial name
- NCT07434869
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Brian Keller
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma
- Trial name
- NCT00008216
- Testing
- Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Columbia University
Heart-lung Transplant Rejection
Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction
The aim of the study is to compare optimal medical therapy alone versus percutaneous coronary intervention on top of medical therapy in the setting of heart transplant recipient coronary artery disease in a randomized trial.The…
- Trial name
- ARCHER (NCT01795729)
- Testing
- Stent, optimal medical therapy
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN)
Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients
Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term.
- Conditions
- Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
- Trial name
- Mini-Kidney (NCT01531257)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Lung Transplant; Complications
4DX Functional Lung Imaging in the Diagnosis of Chronic Lung Allograft Dysfunction After Lung Transplantation
This is a pilot study to determine the utility of Novel Functional Lung Imaging and Ventilation (4DxV) Analysis software in measurement of lung ventilation abnormalities and diagnosis of chronic lung allograft dysfunction (CLAD)…
- Trial name
- NCT04892719
- Testing
- Fluoroscopic chest imaging with 4Dx technology software analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Transplant Rejection, Allograft Rejection
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis…
- Conditions
- Transplant Rejection, Allograft Rejection, Complications
- Trial name
- SPARO (NCT03984747)
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Natera, Inc.
Kidney Transplantation
Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant
The purpose of this study is to determine whether treatment with sirolimus, in combination with low-dose tacrolimus and prednisone, is effective for the treatment of chronic allograft nephropathy (progressive scarring) in…
- Trial name
- NCT00188955
- Testing
- sirolimus
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Manitoba
Graft Rejection, Kidney Transplantation
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
With this project, the research team aims to identify the molecular pathways associated with the response to extracorporeal photonchemioapheresis (ECP) in kidney or lung transplant patients suffering from chronic rejection, by…
- Conditions
- Graft Rejection, Kidney Transplantation, Lung Transplantation, Antibody-Mediated Rejection
- Trial name
- TRACKLESS (NCT07316829)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or…
- Conditions
- Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00105183
- Testing
- EZ-2053, EZ-2053 5mg/kg
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 223 people
- Sponsor
- Neovii Biotech
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
The objective of this trial was to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in double lung transplant (DLT) recipients…
- Conditions
- Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications
- Trial name
- BOSTON-2 (NCT03656926)
- Testing
- Liposomal Cyclosporine A, Standard of Care
- Where
- 40 sites in United States, Austria and 7 more
- Volunteers
- 169 people
- Sponsor
- Zambon SpA
Lung Transplant Rejection
Macitentan in the Treatment of Organ Rejection After Lung Transplantation
Potential therapy with MACITENTAN in the treatment of Chronic Lung Allograft Dysfunction (CLAD) after Lung Transplantation. Pilot Study, Double-blind, "ADD-ON Therapy" with MACITENTAN to "usual standard of care immunosuppressive…
- Trial name
- NCT02893176
- Testing
- macitentan
- Where
- United States
- Sponsor
- University of California, Los Angeles
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
The objective of this trial is to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in single lung transplant recipients with…
- Conditions
- Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications
- Trial name
- BOSTON-1 (NCT03657342)
- Testing
- Liposomal Cyclosporine A, standard of care
- Where
- 39 sites in United States, Belgium and 5 more
- Volunteers
- 62 people
- Sponsor
- Zambon SpA
Bronchiolitis Obliterans Syndrome
A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation
The Primary Objective of this study was to evaluate the FEV1 trajectory of patients diagnosed with CLAD-BOS. The Secondary Objectives of this study were: To describe demographics of patients diagnosed with CLAD-BOS To describe…
- Trial name
- NCT06503770
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 284 people
- Sponsor
- Zambon SpA
Lung Transplant Rejection
Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dysfunction
Lung transplantation is an established therapy for end-stage lung disease such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis and pulmonary hypertension.
- Trial name
- NCT04792294
- Testing
- Extracorporeal photopheresis
- Volunteers
- 800 people
- Sponsor
- Medical University of Vienna
Bronchiolitis Obliterans Syndrome, Graft Rejection
Azithromycin in Bronchiolitis Obliterans Syndrome
Preventive treatment with azithromycin reduces the prevalence fo Bronchiolitis Obliterans Syndrome after lung transplantation.
- Conditions
- Bronchiolitis Obliterans Syndrome, Graft Rejection, Lymphocytic Bronchiolitis, Respiratory Infection
- Trial name
- AZI001 (NCT01009619)
- Testing
- Azithromycin
- Where
- Belgium
- Volunteers
- 83 people
- Sponsor
- KU Leuven
Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation.
- Conditions
- Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
- Trial name
- INSPO-BOS (NCT06018766)
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Steven Hays, MD